(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% $ 1.100
Live Chart Being Loaded With Signals
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device...
Stats | |
---|---|
Volumen de hoy | 1.83M |
Volumen promedio | 1.11M |
Capitalización de mercado | 36.47M |
EPS | $0 ( 2024-03-26 ) |
Próxima fecha de ganancias | ( $0 ) 2024-05-09 |
Last Dividend | $0.200 ( 2014-03-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.553 |
ATR14 | $0.0510 (4.64%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-06-08 | Ra Capital Management, L.p. | Sell | 5 914 252 | Common Stock |
2023-06-08 | Ra Capital Management, L.p. | Sell | 10 000 | Stock Option (Right to Buy) |
2023-06-08 | Ra Capital Management, L.p. | Sell | 20 000 | Stock Option (Right to Buy) |
2023-06-08 | Ra Capital Management, L.p. | Sell | 30 000 | Stock Option (Right to Buy) |
2023-06-06 | O'neil Thomas P. | Sell | 13 877 | Common Stock, $0.0001 par value |
INSIDER POWER |
---|
54.69 |
Last 97 transactions |
Buy: 62 291 817 | Sell: 17 994 879 |
Volumen Correlación
Satsuma Pharmaceuticals Correlación
10 Correlaciones Más Positivas | |
---|---|
NRBO | 0.956 |
DLTH | 0.937 |
NXTC | 0.934 |
TFFP | 0.933 |
TOI | 0.93 |
AGLE | 0.923 |
PRTK | 0.923 |
VIAV | 0.917 |
ONCS | 0.914 |
SGRP | 0.914 |
10 Correlaciones Más Negativas | |
---|---|
AGFS | -0.944 |
APEN | -0.938 |
PRDO | -0.932 |
NRIM | -0.92 |
FANH | -0.916 |
VLYPO | -0.916 |
UFPT | -0.916 |
MACK | -0.914 |
TSBK | -0.91 |
AMRB | -0.906 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Satsuma Pharmaceuticals Correlación - Moneda/Commodity
Satsuma Pharmaceuticals Finanzas
Annual | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-2.16 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $0 (0.00 %) |
EPS: | $-2.16 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.623 |
FY | 2020 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.73 |
Financial Reports:
No articles found.
Satsuma Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.150 | 2012-12-19 |
Last Dividend | $0.200 | 2014-03-28 |
Next Dividend | $0 | N/A |
Payout Date | 2014-04-15 | |
Next Payout Date | N/A | |
# dividends | 7 | -- |
Total Paid Out | $1.500 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.57 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.086 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | 1.339 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 7.44 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.09 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.35 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00267 | -1.500 | 9.96 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 107.96 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.113 | 2.00 | -0.371 | -0.742 | [0 - 30] |
freeCashFlowPerShareTTM | -1.117 | 2.00 | -0.559 | -1.117 | [0 - 20] |
debtEquityRatioTTM | 0.00308 | -1.500 | 9.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -318.09 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.51 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.773 | 1.000 | -0.179 | 0 | [1 - 100] |
returnOnEquityTTM | 1.339 | 2.50 | 1.152 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.117 | 2.00 | -0.372 | -1.117 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.113 | 2.00 | -0.371 | -0.742 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00534 | 1.500 | -3.30 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.623 |
Satsuma Pharmaceuticals
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico